Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
J Med Chem ; 63(13): 7211-7225, 2020 07 09.
Article in English | MEDLINE | ID: mdl-32490678

ABSTRACT

The recent Ebola epidemics in West Africa underscore the great need for effective and practical therapies for future Ebola virus outbreaks. We have discovered a new series of remarkably potent small molecule inhibitors of Ebola virus entry. These 4-(aminomethyl)benzamide-based inhibitors are also effective against Marburg virus. Synthetic routes to these compounds allowed for the preparation of a wide variety of structures, including a conformationally restrained subset of indolines (compounds 41-50). Compounds 20, 23, 32, 33, and 35 are superior inhibitors of Ebola (Mayinga) and Marburg (Angola) infectious viruses. Representative compounds (20, 32, and 35) have shown good metabolic stability in plasma and liver microsomes (rat and human), and 32 did not inhibit CYP3A4 nor CYP2C9. These 4-(aminomethyl)benzamides are suitable for further optimization as inhibitors of filovirus entry, with the potential to be developed as therapeutic agents for the treatment and control of Ebola virus infections.


Subject(s)
Antiviral Agents/pharmacology , Benzamides/pharmacology , Hemorrhagic Fever, Ebola/virology , Marburg Virus Disease/virology , Virus Internalization/drug effects , A549 Cells , Animals , Antiviral Agents/chemistry , Benzamides/chemistry , Chlorocebus aethiops , Cytochrome P-450 CYP3A Inhibitors/chemistry , Cytochrome P-450 CYP3A Inhibitors/pharmacology , Drug Evaluation, Preclinical , Humans , Microsomes, Liver/drug effects , Molecular Docking Simulation , Structure-Activity Relationship , Toremifene/chemistry , Toremifene/metabolism , Toremifene/pharmacology , Vero Cells , Viral Envelope Proteins/chemistry , Viral Envelope Proteins/metabolism
2.
Prostate ; 75(1): 23-32, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25284058

ABSTRACT

BACKGROUND: Prostatic inflammation has been suggested to contribute to the etiology of lower urinary tract symptoms by inducing fibrosis. We previously used a well-characterized mouse model of bacterial-induced prostate inflammation to demonstrate that chronic prostatic inflammation induces collagen deposition. Here, we examined stability of the newly synthesized collagen in bacterial-induced prostatic inflammation and the reversibility of fibrosis after resolution of infection and inflammation. METHODS: Uropathogenic Escherichia coli 1677 was instilled transurethrally into adult C3H/HeOuJ male mice to induce chronic prostatic inflammation. Collagen was labeled by (3) H-proline administration for 28 days post-inoculation and (3) H-hydroxyproline incorporation measured to determine stability of the newly synthesized collagen. Inflammation score was graded using a previously established system and total collagen content was measured by picrosirius red staining quantitation and hydroxyproline content. Resolution of inflammation and reversal of collagen deposition was assessed after treatment with antibiotic enrofloxacin for 2 weeks on day 28 post-inoculation followed by an 8-week recovery period. RESULTS: Decay analysis of incorporated (3) H-hydroxyproline revealed the half-life of newly synthesized collagen to be significantly shorter in infected/inflamed prostates than in controls. Treatment with antibiotic enrofloxacin completely eradicated bacterial infection and allowed resolution of inflammation. This was followed by marked attenuation of collagen content and correlation analysis verified a positive association between the resolution of inflammation and the reversal of collagen deposition. CONCLUSIONS: These data demonstrate, for the first time, that inflammation-induced prostatic fibrosis is a reversible process.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Disease Models, Animal , Escherichia coli Infections/drug therapy , Fluoroquinolones/therapeutic use , Prostate/pathology , Prostatitis/drug therapy , Animals , Bacterial Load , Chromatography, High Pressure Liquid , Collagen/metabolism , Enrofloxacin , Escherichia coli Infections/metabolism , Escherichia coli Infections/microbiology , Fibrosis/physiopathology , Hydroxyproline/metabolism , Male , Mice, Inbred C3H , Prostatitis/metabolism , Prostatitis/microbiology
3.
PLoS One ; 9(6): e100770, 2014.
Article in English | MEDLINE | ID: mdl-24950301

ABSTRACT

Inflammation of the prostate is strongly correlated with development of lower urinary tract symptoms and several studies have implicated prostatic fibrosis in the pathogenesis of bladder outlet obstruction. It has been postulated that inflammation induces prostatic fibrosis but this relationship has never been tested. Here, we characterized the fibrotic response to inflammation in a mouse model of chronic bacterial-induced prostatic inflammation. Transurethral instillation of the uropathogenic E. coli into C3H/HeOuJ male mice induced persistent prostatic inflammation followed by a significant increase in collagen deposition and hydroxyproline content. This fibrotic response to inflammation was accompanied with an increase in collagen synthesis determined by the incorporation of 3H-hydroxyproline and mRNA expression of several collagen remodeling-associated genes, including Col1a1, Col1a2, Col3a1, Mmp2, Mmp9, and Lox. Correlation analysis revealed a positive correlation of inflammation severity with collagen deposition and immunohistochemical staining revealed that CD45+VIM+ fibrocytes were abundant in inflamed prostates at the time point coinciding with increased collagen synthesis. Furthermore, flow cytometric analysis demonstrated an increased percentage of these CD45+VIM+ fibrocytes among collagen type I expressing cells. These data show-for the first time-that chronic prostatic inflammation induces collagen deposition and implicates fibrocytes in the fibrotic process.


Subject(s)
Bacterial Infections/pathology , Fibrosis/pathology , Lower Urinary Tract Symptoms/pathology , Prostatic Diseases/pathology , Animals , Bacterial Infections/complications , Bacterial Infections/microbiology , Collagen Type I/metabolism , Collagen Type I, alpha 1 Chain , Disease Models, Animal , Escherichia coli/pathogenicity , Fibrosis/etiology , Fibrosis/microbiology , Gene Expression Regulation , Humans , Inflammation/complications , Inflammation/pathology , Lower Urinary Tract Symptoms/etiology , Lower Urinary Tract Symptoms/microbiology , Male , Mice , Prostate/metabolism , Prostate/pathology , Prostatic Diseases/etiology , Prostatic Diseases/microbiology
4.
Prostate ; 74(4): 346-58, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24293357

ABSTRACT

BACKGROUND: Prostatic inflammation is an important factor in development and progression of BPH/LUTS. This study was performed to characterize the normal development and vascular anatomy of the mouse prostate and then examine, for the first time, the effects of prostatic inflammation on the prostate vasculature. METHODS: Adult mice were perfused with India ink to visualize the prostatic vascular anatomy. Immunostaining was performed on the E16.5 UGS and the P5, P20, and adult prostate to characterize vascular development. Uropathogenic E. coli 1677 was instilled transurethrally into adult male mice to induce prostate inflammation. RT-PCR and BrdU labeling was performed to assay anigogenic factor expression and endothelial proliferation, respectively. RESULTS: An artery on the ventral surface of the bladder trifurcates near the bladder neck to supply the prostate lobes and seminal vesicle. Development of the prostatic vascular system is associated with endothelial proliferation and robust expression of pro-angiogenic factors Pecam1, Tie1, Tek, Angpt1, Angpt2, Fgf2, Vegfa, Vegfc, and Figf. Bacterial-induced prostatic inflammation induced endothelial cell proliferation and increased vascular density but surprisingly decreased pro-angiogenic factor expression. CONCLUSIONS: The striking decrease in pro-angiogenic factor mRNA expression associated with endothelial proliferation and increased vascular density during inflammation suggests that endothelial response to injury is not a recapitulation of normal development and may be initiated and regulated by different regulatory mechanisms.


Subject(s)
Inflammation/pathology , Neovascularization, Pathologic/pathology , Neovascularization, Physiologic/physiology , Prostate/blood supply , Prostate/growth & development , Animals , Cell Proliferation , Fibroblast Growth Factor 2/genetics , Fibroblast Growth Factor 2/metabolism , Male , Mice , Neovascularization, Pathologic/metabolism , Platelet Endothelial Cell Adhesion Molecule-1/genetics , Platelet Endothelial Cell Adhesion Molecule-1/metabolism , Prostate/metabolism , Prostate/pathology , Vascular Endothelial Growth Factor A/genetics , Vascular Endothelial Growth Factor A/metabolism
5.
Stem Cell Res Ther ; 1(2): 16, 2010 Jun 08.
Article in English | MEDLINE | ID: mdl-20529385

ABSTRACT

Human prostate adenocarcinoma is a multicentric disease with histological heterogeneity and variation in biological features. The present study showed that a cell with stem properties undergoing oncogenic transformation can produce prostate mouse lesions with varied histological phenotypes that resemble different grades of human prostate cancer. This powerful observation is consistent with the notion that a complex spectrum of prostate neoplasms may arise from a common cell of origin, facilitating future studies to understand the development of prostate disease. Even so, it must be noted that there is no conclusive evidence that stem cells are the source of human prostate cancer, and therefore additional studies are required comparing features and natural history of tumors generated by this approach with the process of oncogenesis in the human prostate.


Subject(s)
Adenocarcinoma/etiology , Epithelial Cells/pathology , Neoplastic Stem Cells/pathology , Prostatic Neoplasms/etiology , Animals , Cell Differentiation , Cell Transformation, Neoplastic , Humans , Male , Mice
6.
Mol Pharm ; 5(6): 921-6, 2008.
Article in English | MEDLINE | ID: mdl-19434917

ABSTRACT

Amorphous solids are generally more soluble and faster dissolving than their crystalline counterparts, a property useful for delivering poorly soluble drugs. Amorphous drugs must be stable against crystallization, for crystallization negates their advantages. Recent studies found that crystal growth in amorphous indomethacin is orders of magnitude faster at the free surface than through the bulk and this surface-enhanced crystallization can be inhibited by an ultrathin coating. Herein, we report a second system that exhibits the same phenomena. Crystal growth at the free surface of amorphous nifedipine (NIF) was at least 1 order of magnitude faster than that through the bulk below the glass transition temperature Tg (42 degrees C). A thin coating of gold (10 nm) reduced the surface crystal growth rate to the bulk crystal growth rate. Surface-enhanced crystal growth was more pronounced near and below Tg than substantially above Tg, which suggests that this growth mode is more important for the glassy state. Our results support the view that a thin layer of molecules near the surface have higher mobility than the bulk molecules and can enable faster crystal growth. The higher mobility of surface molecules and the resulting fast crystal growth can be suppressed by an ultrathin coating.


Subject(s)
Gold/chemistry , Nanotechnology/methods , Nifedipine/chemistry , Vasodilator Agents/chemistry , Crystallization , Glass/chemistry , Molecular Structure , Particle Size , Surface Properties , Time Factors , Transition Temperature
SELECTION OF CITATIONS
SEARCH DETAIL
...